A fading ability to smell coffee, flowers, or a gas leak is easy to write off as a side effect of aging or a lingering cold. But a large body of neurological research suggests that a gradual, unexplained loss of smell can be one of the earliest outward signs of a brain disease taking hold, sometimes appearing years before the symptoms doctors usually watch for. The nose, it turns out, sits unusually close to the parts of the brain where several neurodegenerative diseases appear to begin.
The link is strongest for Parkinson’s disease and, to a somewhat lesser degree, Alzheimer’s disease and related dementias. In these conditions, the machinery of smell begins to falter early, often while a person still feels healthy. That timing has made olfactory testing a subject of intense interest for scientists hunting for ways to detect brain disease before it becomes obvious and harder to treat.
Why the olfactory system is vulnerable early
Smell is unusual among the senses in how directly it wires into the brain. Odor molecules stimulate receptor neurons high in the nasal cavity, which pass signals to the olfactory bulb and then into brain regions involved in memory and emotion, largely bypassing the relay station that filters most other sensory input. That short, exposed pathway may leave it particularly susceptible to early damage. A review of olfactory function and cognitive impairment notes that the structures handling smell are among the first affected in several neurodegenerative diseases.
A total loss of smell is called anosmia, while a partial reduction is known as hyposmia. As clinical descriptions of anosmia explain, the causes range from harmless and temporary, such as a head cold or nasal congestion, to serious, including head injury and progressive brain disease. It is the slow, persistent, unexplained decline that most concerns neurologists.
The strong signal in Parkinson’s disease
Nowhere is the connection clearer than in Parkinson’s disease. Studies have found that a large majority of people with Parkinson’s have a measurably impaired sense of smell, and the deficit frequently develops several years before the tremor, stiffness, and slowed movement that define the diagnosis. Some research suggests the disease process may actually begin in the olfactory bulb and lower brainstem before spreading to the movement-control regions.
Because the smell deficit arrives so early, olfactory tests can sometimes distinguish people with Parkinson’s from healthy peers more effectively than motor-function tests. Work summarized in a peer-reviewed analysis of olfaction as an early marker of Parkinson’s and Alzheimer’s disease highlights how consistently this pattern appears across patient groups.
What smell loss can signal about Alzheimer’s
The relationship with Alzheimer’s disease is also well documented, though the deficit tends to be less severe than in Parkinson’s. In long-term studies of older adults, low scores on standardized scratch-and-sniff identification tests have been associated with faster cognitive decline and a higher likelihood of progressing to Alzheimer’s in the following years. The olfactory regions overlap with brain areas where Alzheimer’s-related changes accumulate early, which may explain the connection.
Researchers caution that smell testing alone cannot diagnose these diseases. Many people with reduced smell never develop dementia or Parkinson’s, and the tests are not specific enough to stand on their own. The value lies in using olfaction as one signal among several, potentially flagging people who might benefit from closer monitoring.
The difference between everyday and warning-sign smell loss
Not every dip in smell is a red flag. Temporary loss from a cold, sinus infection, allergies, or a viral illness typically resolves as the underlying problem clears, and a modest decline is a normal part of aging for many people. Medical guidance from sources such as the American Academy of Neurology’s patient publication on smell loss stresses that the concerning pattern is a gradual, unexplained, and persistent decline without an obvious cause like congestion.
Physicians generally recommend that a lasting, unexplained loss of smell be evaluated rather than ignored. The evaluation looks for treatable causes first, since many are reversible, and considers neurological assessment only when the picture warrants it.
The COVID-19 pandemic complicated this picture by making sudden smell loss familiar to millions of people. That viral form typically arrives abruptly and, in most cases, recovers within weeks or months, a pattern quite different from the slow, creeping decline associated with neurodegeneration. Distinguishing a temporary post-viral loss from the gradual erosion that can precede brain disease is part of why clinicians weigh the timing and trajectory of the change rather than the presence of smell loss alone.
Why researchers are watching the nose so closely
The broader significance of these findings is timing. Neurodegenerative diseases are believed to begin years or even decades before diagnosis, and by the time classic symptoms appear, substantial numbers of brain cells may already be lost. A cheap, noninvasive smell test that flags risk early could become a valuable screening tool, especially as scientists work toward treatments that might slow disease progression.
For now, olfactory testing remains mostly a research and supporting tool rather than a routine screen. But the consistent thread running through the studies is hard to ignore: a sense often taken for granted may quietly track the earliest stirrings of disease deep in the brain, long before anything else gives it away. That is why a persistent, unexplained fading of smell is increasingly treated by specialists not as a trivial nuisance but as a signal worth taking seriously and investigating properly.
This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.
More from Morning Overview
